The Times Australia
News From Asia

.
The Times Real Estate

.

CK Life Sciences’ Investigational Cancer Vaccines Deliver Promising Results - New Preclinical Study Data to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

HONG KONG SAR - Media OutReach Newswire - 22 April 2025 - CK Life Sciences Int'l., (Holdings) Inc. ("the Company") announced that the Company will be presenting new data from its cancer vaccine research pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.



The AACR Annual Meeting is a gathering central to the global cancer research community, bringing together scientists, clinicians, other healthcare professionals, survivors, patients and advocates every year to share the latest breakthroughs and developments in cancer science and medicine. Last year, the 2024 Annual Meeting attracted 23,000 in-person attendees and 6,700 online participants from 78 countries.

In recent years, CK Life Sciences has regularly participated at the AACR Annual Meeting. The 2025 Annual Meeting will be held from 25-30 April. At the event, CK Life Sciences will exhibit posters highlighting data from preclinical studies of investigational cancer vaccines programs targeting (i) PRAME (Preferentially Expressed Antigen in Melanoma), (ii) PD-L1 (programmed cell death ligand 1), (iii) B7-H3 (B7 homolog 3) and (iv) Claudin 6 proteins, respectively.

PRAME is a protein highly expressed in several cancers, including melanoma, liver cancer and leukemia.

PD-L1 is one of the most important immune checkpoint proteins that is highly expressed in cancer cells to block T cell activation in the tumour microenvironment.

B7-H3 is another immune checkpoint protein that modulates T cell responses and is often overexpressed in cancer.

Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in cancers like breast cancer, lung cancer and endometrial cancer, where it is associated with tumour progression and metastasis.

In addition, CK Life Sciences will be co-presenting with our research collaborator two posters showcasing our Artificial Intelligence (AI)-empowered platform for designing cancer vaccines.

"CK Life Sciences is pleased with the preclinical efficacy results of its investigational cancer vaccines targeting PRAME, PD-L1, B7-H3 and Claudin 6 proteins, and we hope to further advance the research & development of these and other cancer vaccines. We are also excited about the progress achieved in our efforts to develop an AI platform aimed at designing cancer vaccines that are more likely to be immunogenic and clinically effective," said Melvin Toh, Vice President and Chief Scientific Officer at CK Life Sciences.

Dr. Toh continued, "CK Life Sciences is determined to accelerate its R&D to benefit cancer patients. Currently, a number of therapeutic cancer vaccines are in clinical and discovery/preclinical research stages. Amongst them, seviprotimut-L, a cancer vaccine already in the final research stage, is being tested for the adjuvant treatment of stage IIB or IIC melanoma following definitive surgical resection.

DETAILS ON POSTER PRESENTATIONS:

  • Abstract 853: PDL1-PRAME dual antigen cancer vaccine inhibits melanoma growth in syngeneic mouse model and induces antigen-specific immune responses
Authors: Kin-Tak Chan, Hsin-Wei Chen, Pi-Hui Liang, You-Yu Lin, Tristan Zhang, Melvin Toh

Session Category: Clinical Research
Session Title: Vaccines and Cell Therapies
Session Date and Time: 4/27/2025 2:00 PM - 5:00 PM
Location: Poster Section 35
Poster Board Number: 9

  • Abstract 3533: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model
Authors: Na Wang, Melvin Toh, Hong Wang

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 9

  • Abstract 3536: Synergistic effects of combined PD-L1 and B7-H3 fusion protein vaccination in a mouse model of pancreatic cancer
Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 12

  • Abstract 3538: The development of neoantigen-derived peptide vaccine driven by AI epitope design and computer assisted epitope enhancement
Authors: Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Jiewen Du, Lipeng Lai, Melvin Toh

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 14

  • Abstract 3649: Artificial intelligence accelerates shared neoantigen peptide cancer vaccine development
Authors: Genwei Zhang, Jiewen Du, Xiangrui Gao, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Chi Han Samson Li, Kin Tak Chan, Hong Wang, Melvin Toh, Lipeng Lai

Session Category: Bioinformatics/ Computational Biology/ Systems Biology/ Convergent Science
Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 45
Poster Board Number: 11

The full abstracts are available in the AACR Online Itinerary Planner, which can be accessed at: https://www.abstractsonline.com/pp8/#!/20273

DISCLAIMER
This press release may contain forward-looking statements regarding the Group’s research and development projects which may involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements.
All information in this press release is for general reference only and is not intended as investment advice or medical advice. CK Life Sciences Int'l., (Holdings) Inc. does not warrant or represent, express or implied, as to the accuracy, completeness or updated status of such information. No liability will be accepted for any loss or damage howsoever arising from or in reliance upon such information.

Copyright ©2025 CK Life Sciences Int’l., (Holdings) Inc. All rights reserved.

Hashtag: #CKLifeSciences #CancerVaccines #R&D #Pharmaceutical #AmericanAssociationforCancerResearch #AACR #PRAME #PD-L1 #B7-H3 #Claudin6Proteins #Melanoma #AI

The issuer is solely responsible for the content of this announcement.

The Times Features

Sorbet Balls by bubbleme Bring Bite-Sized Cool Spin to Frozen Snacking

A cool new frozen treat is rolling into the ice-cream aisle at Woolworths stores nationwide. Dairy-free, gluten-free and free from artificial colours, bubbleme Sorbet Balls ar...

Mind-Body Balance: The Holistic Approach of Personal Training in Moonee Ponds

Key Highlights Discover the benefits of a holistic approach to personal training in Moonee Ponds and nearby Maribyrnong, including residents from Strathmore. Learn how mind-b...

How Online Platforms Empower You to Find Affordable Removalists and Electricity Plans

When you move into a new home, you have many tasks to do. You need to hire removalists and set up your electricity.  In this article, we discuss how online platforms empower you ...

IS ROSEMARY OIL THE SECRET TO BETTER HAIR DAYS? HERE’S WHAT IT CAN DO

Rosemary hair oil is a straightforward natural solution that delivers exceptional results for anyone who wants to enhance their haircare process. It maintains its status in herba...

How to Choose the Right Nail Supplies for Your Nail Type

Where gorgeous, healthy nails are concerned, one size absolutely doesn’t fit all. As your skin and hair, your nails have special needs too and using products that aren’t right fo...

Epoxy Flooring: The Future of Residential Flooring in Australia

Epoxy flooring is rapidly emerging as the top flooring solution for Australian homeowners. Traditionally associated with industrial and commercial spaces, epoxy coatings are now ...

Times Magazine

CNC Machining Meets Stage Design - Black Swan State Theatre Company & Tommotek

When artistry meets precision engineering, incredible things happen. That’s exactly what unfolded when Tommotek worked alongside the Black Swan State Theatre Company on several of their innovative stage productions. With tight deadlines and intrica...

Uniden Baby Video Monitor Review

Uniden has released another award-winning product as part of their ‘Baby Watch’ series. The BW4501 Baby Monitor is an easy to use camera for keeping eyes and ears on your little one. The camera is easy to set up and can be mounted to the wall or a...

Top Benefits of Hiring Commercial Electricians for Your Business

When it comes to business success, there are no two ways about it: qualified professionals are critical. While many specialists are needed, commercial electricians are among the most important to have on hand. They are directly involved in upholdin...

The Essential Guide to Transforming Office Spaces for Maximum Efficiency

Why Office Fitouts MatterA well-designed office can make all the difference in productivity, employee satisfaction, and client impressions. Businesses of all sizes are investing in updated office spaces to create environments that foster collaborat...

The A/B Testing Revolution: How AI Optimized Landing Pages Without Human Input

A/B testing was always integral to the web-based marketing world. Was there a button that converted better? Marketing could pit one against the other and see which option worked better. This was always through human observation, and over time, as d...

Using Countdown Timers in Email: Do They Really Increase Conversions?

In a world that's always on, where marketers are attempting to entice a subscriber and get them to convert on the same screen with one email, the power of urgency is sometimes the essential element needed. One of the most popular ways to create urg...

LayBy Shopping